Superworth

Corcept Therapeutics EV/EBIT CORT

Enterprise value divided by operating profit over the last twelve months, one-off items taken out, since 2016.

Today, Oct 23, 2026
n/m
a sliver of operating profit
Last meaningful
101×
Apr 2026
10-year median
19.7×
10-year range
7.5× to 193×
Peer median
56.1×

Corcept Therapeutics' EV/EBIT is not a meaningful number today: a multiple this high rests on a sliver of operating profit.

It was last meaningful in Apr 2026, at 101×.

On the days it had one over the last ten years, its median was 19.7×, from 7.5× in Aug 2020 to 193× in Oct 2016.

EV/EBIT over time

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far101×49.4×101×
2025126×33.8×135×
202435.7×16.7×41.8×
202326.7×13.0×27.2×
202214.1×12.7×20.6×
202116.3×15.3×22.5×
202019.7×7.5×20.6×
201911.6×10.7×17.7×
201815.2×13.8×77.1×
201754.9×50.3×154×
2016114×114×490×

Against its peers

Companies in Drug Manufacturers - General nearest Corcept Therapeutics' size, closest first, today.

CompanyEV/EBIT
CORTCorcept Therapeuticsn/m
PTGXProtagonist Therapeutics140×
TGTXTG Therapeutics62.2×
BMRNBiomarin Pharmaceutical25.8×
ALKSAlkermes plc.69.6×
AMRXAmneal Pharmaceuticals18.3×
JAZZJazz Pharmaceuticals15.9×
LGNDLigand Pharmaceuticals57.7×
KNSAKiniksa Pharmaceuticals International54.6×
INDVIndivior Pharmaceuticals7.8×
ARQTArcutis Biotherapeutics111×
Peer median56.1×

What the EV/EBIT tells you

What the whole business costs against its operating profit. Enterprise value is the market value plus borrowings and minority interests, less cash. EBIT is operating profit before interest and tax, with one-offs taken out. Unlike PE it is not moved by how a company is financed.

Leases are left out of debt for every company. Banks earn on their balance sheet, so EV/EBIT does not describe them.

More on Corcept Therapeutics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.